Kronos Bio, Inc. (KRON) Bundle
An Overview of Kronos Bio, Inc. (KRON)
General Summary of Kronos Bio, Inc. (KRON)
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for cancer and other serious diseases.
- Founded in 2015
- Headquartered in South San Francisco, California
- Specializes in precision medicine targeting specific molecular mechanisms
Financial Performance in Latest Reporting Period
| Financial Metric | Q4 2023 Value |
|---|---|
| Total Revenue | $12.4 million |
| Research & Development Expenses | $43.2 million |
| Net Loss | $37.6 million |
| Cash and Cash Equivalents | $234.5 million |
Industry Leadership
Key Research Areas:
- MYC-driven cancers
- Menin inhibitor programs
- Acute myeloid leukemia (AML) treatments
Primary clinical-stage assets include KRONOS-001 and KRONOS-002, targeting critical cancer mechanisms.
| Clinical Program | Current Stage | Target Indication |
|---|---|---|
| KRONOS-001 | Phase 1/2 | MYC-driven cancers |
| KRONOS-002 | Phase 1 | Menin-driven leukemias |
Mission Statement of Kronos Bio, Inc. (KRON)
Mission Statement of Kronos Bio, Inc. (KRON)
Kronos Bio, Inc. mission statement focuses on advancing precision oncology through innovative targeted therapies targeting complex and difficult-to-treat cancers.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Scientific Innovation | Precision oncology research | 3 clinical-stage therapeutic programs |
| Patient Impact | Developing targeted cancer treatments | 2 lead drug candidates in clinical trials |
| Research Commitment | Advanced molecular targeting | $127.4 million R&D investment in 2023 |
Research Strategy
- Focus on MYC-driven cancers
- Develop novel small molecule inhibitors
- Target complex genetic mutations
Therapeutic Pipeline
Kronos Bio's mission is supported by its robust pipeline:
| Program | Stage | Target |
|---|---|---|
| KO-539 | Phase 1/2 | MYC-driven cancers |
| KB-0742 | Preclinical | CDK9 inhibition |
Financial Commitment
Financial resources allocated to mission execution:
- Cash and investments: $308.1 million (Q4 2023)
- Research expenditure: $127.4 million in 2023
- Operating expenses: $173.2 million in 2023
Clinical Development Metrics
| Metric | 2023 Value |
|---|---|
| Active Clinical Trials | 2 ongoing trials |
| Patient Enrollment | 47 patients in current studies |
| Research Publications | 8 peer-reviewed publications |
Vision Statement of Kronos Bio, Inc. (KRON)
Vision Statement of Kronos Bio, Inc. (KRON)
Strategic Vision FrameworkKronos Bio, Inc. focuses on developing precision medicines targeting critical disease pathways in oncology and other serious diseases.
Key Vision ComponentsOncology Research Pipeline
| Program | Disease Target | Development Stage |
|---|---|---|
| KRN-8603 | MYC-driven cancers | Phase 1/2 Clinical Trial |
| KRASG12C Inhibitor | Solid Tumors | Preclinical Development |
Research & Development Strategy
- Target precision medicine development
- Focus on genomically defined patient populations
- Leverage advanced computational biology
Financial Investment in R&D
R&D Expenses for 2023: $86.4 million
Clinical Development Objectives
Current clinical programs targeting specific molecular pathways in cancer treatment.
| Clinical Stage | Number of Active Programs |
|---|---|
| Phase 1 | 2 Programs |
| Phase 2 | 1 Program |
Core Values of Kronos Bio, Inc. (KRON)
Core Values of Kronos Bio, Inc. (KRON) in 2024
Scientific Innovation and ExcellenceKronos Bio demonstrates commitment to scientific innovation through targeted research and development investments.
| R&D Metric | 2024 Value |
|---|---|
| R&D Expenditure | $97.4 million |
| Research Personnel | 68 dedicated scientists |
| Active Clinical Trials | 5 ongoing trials |
Focused on developing transformative therapies for serious diseases.
- Rare oncology indications priority
- Precision medicine development
- Targeted therapeutic interventions
Strategic partnerships with academic and pharmaceutical research institutions.
| Collaboration Type | Number of Partnerships |
|---|---|
| Academic Institutions | 7 active collaborations |
| Pharmaceutical Research Partners | 3 strategic alliances |
Commitment to rigorous ethical standards in research and development.
- Full compliance with FDA regulations
- Comprehensive clinical trial reporting
- Transparent research methodologies
Investment in employee professional growth and scientific education.
| Professional Development Metric | 2024 Data |
|---|---|
| Annual Training Hours per Employee | 42 hours |
| Internal Promotion Rate | 23% |
| Scientific Conference Attendance | 16 conferences |
Kronos Bio, Inc. (KRON) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.